163 related articles for article (PubMed ID: 37402882)
41. [Evaluation of two-tier grading system and significance of p53 protein over-expression in ovarian serous carcinoma].
Lin J; Du J; Zhang CY; Xie QT; Zhang B; Liu CR
Zhonghua Bing Li Xue Za Zhi; 2010 Oct; 39(10):655-60. PubMed ID: 21176529
[TBL] [Abstract][Full Text] [Related]
42. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.
Hofstetter G; Berger A; Schuster E; Wolf A; Hager G; Vergote I; Cadron I; Sehouli J; Braicu EI; Mahner S; Speiser P; Marth C; Zeimet AG; Ulmer H; Zeillinger R; Concin N
Br J Cancer; 2011 Nov; 105(10):1593-9. PubMed ID: 22009029
[TBL] [Abstract][Full Text] [Related]
43. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
44. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
Köbel M; Kang EY; Weir A; Rambau PF; Lee CH; Nelson GS; Ghatage P; Meagher NS; Riggan MJ; Alsop J; Anglesio MS; Beckmann MW; Bisinotto C; Boisen M; Boros J; Brand AH; Brooks-Wilson A; Carney ME; Coulson P; Courtney-Brooks M; Cushing-Haugen KL; Cybulski C; Deen S; El-Bahrawy MA; Elishaev E; Erber R; Fereday S; ; Fischer A; Gayther SA; Barquin-Garcia A; Gentry-Maharaj A; Gilks CB; Gronwald H; Grube M; Harnett PR; Harris HR; Hartkopf AD; Hartmann A; Hein A; Hendley J; Hernandez BY; Huang Y; Jakubowska A; Jimenez-Linan M; Jones ME; Kennedy CJ; Kluz T; Koziak JM; Lesnock J; Lester J; Lubiński J; Longacre TA; Lycke M; Mateoiu C; McCauley BM; McGuire V; Ney B; Olawaiye A; Orsulic S; Osorio A; Paz-Ares L; Ramón Y Cajal T; Rothstein JH; Ruebner M; Schoemaker MJ; Shah M; Sharma R; Sherman ME; Shvetsov YB; Singh N; Steed H; Storr SJ; Talhouk A; Traficante N; Wang C; Whittemore AS; Widschwendter M; Wilkens LR; Winham SJ; Benitez J; Berchuck A; Bowtell DD; Candido Dos Reis FJ; Campbell I; Cook LS; DeFazio A; Doherty JA; Fasching PA; Fortner RT; García MJ; Goodman MT; Goode EL; Gronwald J; Huntsman DG; Karlan BY; Kelemen LE; Kommoss S; Le ND; Martin SG; Menon U; Modugno F; Pharoah PD; Schildkraut JM; Sieh W; Staebler A; Sundfeldt K; Swerdlow AJ; Ramus SJ; Brenton JD
J Pathol Clin Res; 2023 May; 9(3):208-222. PubMed ID: 36948887
[TBL] [Abstract][Full Text] [Related]
45. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.
Yemelyanova A; Vang R; Kshirsagar M; Lu D; Marks MA; Shih IeM; Kurman RJ
Mod Pathol; 2011 Sep; 24(9):1248-53. PubMed ID: 21552211
[TBL] [Abstract][Full Text] [Related]
46. Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma.
Novak M; Lester J; Karst AM; Parkash V; Hirsch MS; Crum CP; Karlan BY; Drapkin R
Gynecol Oncol; 2015 Oct; 139(1):104-11. PubMed ID: 26206555
[TBL] [Abstract][Full Text] [Related]
47. Two different, mutually exclusively distributed,
Sukhbaatar N; Bachmayr-Heyda A; Auer K; Aust S; Deycmar S; Horvat R; Pils D
Cold Spring Harb Mol Case Stud; 2017 Jul; 3(4):. PubMed ID: 28679689
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
[TBL] [Abstract][Full Text] [Related]
49. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
50. Risk factors for a serous cancer precursor ("p53 signature") in women with inherited BRCA mutations.
Saleemuddin A; Folkins AK; Garrett L; Garber J; Muto MG; Crum CP; Tworoger S
Gynecol Oncol; 2008 Nov; 111(2):226-32. PubMed ID: 18718648
[TBL] [Abstract][Full Text] [Related]
51. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
53. [Clinicopathologic study and immunohistochemistry comparison of Pax2, p53 and Ki-67 in low- and high-grade ovarian serous carcinomas].
Shen XX; Yu L; Bi R; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):511-6. PubMed ID: 22169637
[TBL] [Abstract][Full Text] [Related]
54. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions.
Wu NY; Fang C; Huang HS; Wang J; Chu TY
Mod Pathol; 2020 Jan; 33(1):29-37. PubMed ID: 31558785
[TBL] [Abstract][Full Text] [Related]
55. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.
Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL
J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554
[TBL] [Abstract][Full Text] [Related]
56. A comparison of four technologies for detecting p53 aggregates in ovarian cancer.
Heinzl N; Koziel K; Maritschnegg E; Berger A; Pechriggl E; Fiegl H; Zeimet AG; Marth C; Zeillinger R; Concin N
Front Oncol; 2022; 12():976725. PubMed ID: 36158680
[TBL] [Abstract][Full Text] [Related]
57. Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers.
Tuna M; Ju Z; Yoshihara K; Amos CI; Tanyi JL; Mills GB
Br J Cancer; 2020 Feb; 122(3):405-412. PubMed ID: 31780779
[TBL] [Abstract][Full Text] [Related]
58. Survivin, sonic hedgehog, krüppel-like factors, and p53 pathway in serous ovarian cancer: an immunohistochemical study.
Londero AP; Orsaria M; Viola L; Marzinotto S; Bertozzi S; Galvano E; Andreetta C; Mariuzzi L
Hum Pathol; 2022 Sep; 127():92-101. PubMed ID: 35777700
[TBL] [Abstract][Full Text] [Related]
59. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.
Concin N; Hofstetter G; Berger A; Gehmacher A; Reimer D; Watrowski R; Tong D; Schuster E; Hefler L; Heim K; Mueller-Holzner E; Marth C; Moll UM; Zeimet AG; Zeillinger R
Clin Cancer Res; 2005 Dec; 11(23):8372-83. PubMed ID: 16322298
[TBL] [Abstract][Full Text] [Related]
60. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
Ahmed AA; Etemadmoghadam D; Temple J; Lynch AG; Riad M; Sharma R; Stewart C; Fereday S; Caldas C; Defazio A; Bowtell D; Brenton JD
J Pathol; 2010 May; 221(1):49-56. PubMed ID: 20229506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]